Skip to content

PolitiKit

Lobbying by Novartis Pharmaceuticals Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Corporation

Novartis Pharmaceuticals Canada Inc.

Meetings this Parliament
36
With MPs
15
Since Nov 2021
93
Active registrations
1

Most recent reported meeting: Sep 23, 2026.

Registrations in effect

In-house (corporation) In effect since May 19, 2026

Filed by Dimitri Gitas, Country President

Lobbyists

  • Guillaume Demers · Director - Public Affairs
  • Shona Kinley · Vice-President Public Affairs Former public office holder

    Formerly Special Assistant, Minister's Office, Health Canada (1996–1996)

Institutions they may lobby: Atlantic Canada Opportunities Agency (ACOA), Canadian Heritage (PCH), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Natural Resources Canada (NRCan), Pacific Economic Development Canada (PacifiCan), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)

What they're lobbying on (9)
  • The CUSMA renegotiation and issues related to the pharmaceutical industry in Canada.
  • Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, as well as the Intellectual Property performance review, as noted in budget 2026.
  • Free trade agreements as they relate to biomanufacturing industry in Canada. Engage, as a stakeholder, to provide input into the re-negotiation of the Canada USA Mexico trade agreement "CUSMA"
  • Patented Medicines Regulations modernization as outlined in Budget 2026, that will leverage existing technology, enabling faster and more cost effective procedural processes.
  • Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
  • R&D requirements set forth through the Patent Medicines Pricing Review Board (PMPRB)
  • Patented Medicine Prices Review Board (PMPRB) Regulations as related to reporting requirements and pricing guidelines.
  • Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries
  • Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.

Registration 962869-15599-43. Look it up in the official Registry

Reported meetings

Spreadsheet

Filed by Mark Vineis (35), Dimitri Gitas (21), Andrea Marazzi (17), Christian Macher (14), Pedro Ferreira (6).

  • Reported by Andrea Marazzi · In-house (corporation)

    HealthIndustry

    Official report

  • Reported by Andrea Marazzi · In-house (corporation)

    • Seamus O'Regan · Minister of Labour, Employment and Social Development Canada (ESDC)

    HealthIndustry

    Official report

  • Reported by Andrea Marazzi · In-house (corporation)

    • Simon Kennedy · Sous-ministre, Innovation, Science and Economic Development Canada (ISED)

    HealthIndustryIntellectual PropertyInternational TradeScience and Technology

    Official report

  • Reported by Andrea Marazzi · In-house (corporation)

    • Stephen Lucas · Sous-ministre, Health Canada (HC)
    • Nancy Hamzawi · Assistant Deputy Minister, Health Canada (HC)

    HealthIndustryIntellectual PropertyInternational TradeScience and Technology

    Official report

  • Reported by Christian Macher · In-house (corporation)

    • Alexandre Boulerice · Member of Parliament, House of Commons

    HealthIndustry

    Official report

  • Reported by Christian Macher · In-house (corporation)

    and 1 more
    • Richard Martel · Member of Parliament, House of Commons

    HealthIndustry

    Official report

  • Reported by Christian Macher · In-house (corporation)

    Health

    Official report

  • Reported by Christian Macher · In-house (corporation)

    • Stephen Ellis · Member of Parliament, House of Commons

    Health

    Official report

  • Reported by Christian Macher · In-house (corporation)

    • Jean-Yves Duclos · Minister of Health, Health Canada (HC)
    • Jean-Sébastien Bock · Director of Policy, Health Canada (HC)
    • Jamie Kippen · Chief of Staff, Health Canada (HC)
    • Karl Sasseville · Deputy Chief of Staff, Health Canada (HC)
    and 1 more
    • Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)

    Health

    Official report

  • Reported by Christian Macher · In-house (corporation)

    • Simon Kennedy · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Eric Costen · Senior Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)

    HealthIndustryScience and Technology

    Official report

  • Reported by Christian Macher · In-house (corporation)

    • Sandenga Yeba · Conseiller principal, Politiques - bureau de Quebec, Health Canada (HC)

    Health

    Official report

  • Reported by Christian Macher · In-house (corporation)

    • Tom Kmiec · Member of Parliament, Calgary Shephard

    HealthResearch and Development

    Official report

  • Reported by Christian Macher · In-house (corporation)

    • Jean-Sébastien Bock · Directeur des politiques, Health Canada (HC)

    Health

    Official report

  • Reported by Christian Macher · In-house (corporation)

    Health

    Official report

  • Reported by Christian Macher · In-house (corporation)

    Health

    Official report

  • Reported by Christian Macher · In-house (corporation)

    Health

    Official report

  • Reported by Christian Macher · In-house (corporation)

    • Jean-Sebastien Bock · Director of Policy, Health Canada (HC)
    • Miro Froehlich · Policy Advisor, Health Canada (HC)

    Health

    Official report

  • Reported by Christian Macher · In-house (corporation)

    • Marc Miller · Minister of Indigenous Services, Indigenous Services Canada (ISC)

    HealthIndustryScience and Technology

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.